S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NYSE:BMY

Bristol-Myers Squibb Competitors

$60.43
+1.09 (+1.84 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.33
Now: $60.43
$60.59
50-Day Range
$59.34
MA: $62.17
$66.74
52-Week Range
$45.76
Now: $60.43
$67.16
Volume14.98 million shs
Average Volume13.12 million shs
Market Capitalization$135.39 billion
P/E RatioN/A
Dividend Yield3.23%
Beta0.67

Competitors

Bristol-Myers Squibb (NYSE:BMY) Vs. JNJ, LLY, PFE, ABBV, MRK, and ZTS

Should you be buying BMY stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Bristol-Myers Squibb, including Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Zoetis (ZTS).

Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Johnson & Johnson21.01%34.64%13.40%

Earnings and Valuation

This table compares Bristol-Myers Squibb and Johnson & Johnson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
Johnson & Johnson$82.06 billion5.00$15.12 billion$8.6817.98

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Johnson & Johnson031202.80

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Johnson & Johnson has a consensus target price of $178.9333, indicating a potential upside of 14.63%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Johnson & Johnson.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 11 of the 18 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Eli Lilly and24.01%166.45%15.18%

Earnings and Valuation

This table compares Bristol-Myers Squibb and Eli Lilly and's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
Eli Lilly and$22.32 billion8.89$8.32 billion$6.0434.26

Eli Lilly and has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Eli Lilly and, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Eli Lilly and041012.80

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Eli Lilly and has a consensus target price of $192.60, indicating a potential downside of 6.92%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Eli Lilly and.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Eli Lilly and beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Pfizer17.85%24.88%9.32%

Earnings and Valuation

This table compares Bristol-Myers Squibb and Pfizer's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
Pfizer$51.75 billion3.71$16.27 billion$2.9511.66

Pfizer has higher revenue and earnings than Bristol-Myers Squibb. Pfizer is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Pfizer010402.29

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Pfizer has a consensus target price of $39.5333, indicating a potential upside of 14.96%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Pfizer.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.5%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Summary

Bristol-Myers Squibb beats Pfizer on 11 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Bristol-Myers Squibb and AbbVie's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
AbbVie$33.27 billion5.66$7.88 billion$8.9411.94

AbbVie has higher revenue and earnings than Bristol-Myers Squibb. AbbVie is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and AbbVie, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
AbbVie131402.72

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. AbbVie has a consensus target price of $115.50, indicating a potential upside of 8.25%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than AbbVie.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
AbbVie18.16%439.24%13.22%

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

AbbVie beats Bristol-Myers Squibb on 12 of the 18 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
Merck & Co., Inc.$46.84 billion3.95$9.84 billion$5.1914.09

Merck & Co., Inc. has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Merck & Co., Inc., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Merck & Co., Inc.021302.87

Bristol-Myers Squibb presently has a consensus price target of $74.6429, indicating a potential upside of 23.52%. Merck & Co., Inc. has a consensus price target of $95.3571, indicating a potential upside of 30.39%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Bristol-Myers Squibb.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Profitability

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Merck & Co., Inc.24.33%53.83%16.83%

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Bristol-Myers Squibb on 13 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88
Zoetis$6.26 billion11.06$1.50 billion$3.6440.02

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Bristol-Myers Squibb and Zoetis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Zoetis07702.50

Bristol-Myers Squibb presently has a consensus price target of $74.6429, suggesting a potential upside of 23.52%. Zoetis has a consensus price target of $167.7273, suggesting a potential upside of 15.13%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, research analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.7%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Zoetis pays out 27.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 1 consecutive years and Zoetis has raised its dividend for 1 consecutive years.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Zoetis25.50%63.89%14.99%

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zoetis beats Bristol-Myers Squibb on 9 of the 17 factors compared between the two stocks.


Bristol-Myers Squibb Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.8$156.10+1.9%$410.34 billion$82.06 billion24.54
Eli Lilly and logo
LLY
Eli Lilly and
2.1$206.92+3.1%$198.32 billion$22.32 billion33.81Gap Up
Pfizer logo
PFE
Pfizer
2.6$34.39+0.6%$191.81 billion$51.75 billion22.19
AbbVie logo
ABBV
AbbVie
2.8$106.70+1.0%$188.42 billion$33.27 billion22.56Insider Selling
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$73.13+1.3%$185.04 billion$46.84 billion16.18
Zoetis logo
ZTS
Zoetis
2.3$145.68+1.2%$69.22 billion$6.26 billion43.23
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$88.65+2.8%$19.86 billion$1.30 billion24.22
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.54+0.5%$16.51 billionN/A0.00Insider Selling
News Coverage
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$164.75+2.6%$9.28 billion$2.16 billion51.97Analyst Report
Increase in Short Interest
Perrigo logo
PRGO
Perrigo
2.6$41.04+1.1%$5.46 billion$4.84 billion-683.89Earnings Announcement
Analyst Report
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.1$22.31+0.3%$4.06 billion$114.62 million-9.00Analyst Revision
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$69.20+2.9%$3.04 billion$421.03 million24.37
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.55+2.9%$2.88 billion$306.49 million27.58
Endo International logo
ENDP
Endo International
1.1$6.99+1.4%$1.61 billion$2.91 billion-10.28Analyst Report
Analyst Revision
News Coverage
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.6$25.15+4.0%$1.32 billion$392.76 million10.43Analyst Downgrade
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$20.74+2.3%$1.15 billion$3.65 million-2.18
Omeros logo
OMER
Omeros
1.4$18.48+4.1%$1.14 billion$111.81 million-7.76Earnings Announcement
Analyst Revision
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.05+0.7%$409.50 million$111.39 million28.93Upcoming Earnings
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.10+0.6%$324.05 million$16.54 million-2.89Analyst Report
Analyst Revision
News Coverage
Lannett logo
LCI
Lannett
2.0$6.17+2.1%$255.45 million$545.74 million-8.57Gap Up
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.48+3.3%$171.34 million$15.96 million-2.72Analyst Report
Analyst Revision
Gap Down
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.12+2.6%$46.78 million$47.53 million-14.16Upcoming Earnings
Gap Down
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.